Phaseline

Targets › RNASE1

RNASE1 (Ribonuclease pancreatic): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout May 2027.

Endonuclease that catalyzes the cleavage of RNA on the 3' side of pyrimidine nucleotides. Acts on single-stranded and double-stranded RNA. (UniProt, P07998)

Open in Phaseline: the race on RNASE1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Resolve TherapeuticsRSLV-132
Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to hu
RNASE1Phase 2Primary Sjögren SyndromeMay 2027

Conditions

Primary Sjögren Syndrome (1)

Modalities

small molecule (1)

Companies

Resolve Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.